Rock Creek Pharmaceuticals, Inc. (OTCQB: RCPI) is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases, according to the company’s website (see here: www.RockCreekPharmaceuticals.com). SNNLive spoke with Dr. Michael Mullan, CEO and Chairman of the Board for Rock Creek Pharmaceuticals, Inc. at Healthcare Week 2016 in San Francisco, CA.
In this video interview, Dr. Mullan and our host discuss the following topics:
- Overview of Rock Creek Pharmaceuticals, Inc.
- Background on the company and Dr. Mullan
- Discusses the company’s science
- Where the company’s formulations and compounds were developed
- Target indications
- Clinical Development
- Goals and milestones for 2016
For more information about Rock Creek Pharmaceuticals, Inc., go to: www.RockCreekPharmaceuticals.com
The interview may contain forward looking statements about Rock Creek Pharmaceuticals, Inc. See Rock Creek's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions